373 0 Kommentare The Life Sciences Report Examines Resverlogix's New Trial

SAN FRANCISCO, CA--(Marketwired - August 04, 2016) - With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix Corp. (TSX: RVX) has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications.

Included in this article is: Resverlogix Corp.

Marcel Wijma, CEO and managing director of Van Leeuwenhoeck Research, when asked to comment on Resverlogix, said, "Resverlogix announced that it started a new Phase 1 trial with its lead drug apabetalone in patients with severe kidney disease. If successful, the clinical results will allow for more advanced kidney impairment and dialysis trials to proceed. The results are expected before the end of the year. This new trial is part of the company's strategy to expand its clinical program with apabetalone (RVX-208) into new indications and orphan diseases."

According to Wijma, Resverlogix had announced earlier that it intended to "initiate an Orphan Disease Program that will target diseases where BET inhibition may hold a promising approach. This will increase the probability that apabetalone can be filed for approval much earlier than anticipated with the current Phase 3 BETonMACE trial in high-risk cardiovascular patients. Also, pricing for rare indications could run into hundreds of thousands per patient per year. We also feel that this would increase the company's chances to make successful partnerships with pharmaceutical companies in different parts of the world."

Continue reading this article: Resverlogix Seeks Orphan Status for Lead Drug Candidate

About Streetwise Reports -- The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

The following companies mentioned in the article are sponsors of Streetwise Reports: Resverlogix Corp. The companies mentioned in this article were not involved in any aspect of the article preparation. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

The full disclosure is provided at the end of the published article: Resverlogix Seeks Orphan Status for Lead Drug Candidate